Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.58 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.58 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.58 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 3/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL330364 | 0.97 | KMT2A (0.61) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL330002 | 0.97 | KMT2A (0.61) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL329999 | 0.97 | KMT2A (0.61) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| SCHEMBL5295760 | 0.95 | KCNH2 (0.56) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| SCHEMBL5304743 | 0.95 | KCNH2 (0.56) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| SCHEMBL5815089 | 0.95 | KCNH2 (0.56) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| SCHEMBL5819151 | 0.95 | KCNH2 (0.56) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| SCHEMBL5289064 | 0.95 | KCNH2 (0.56) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| SCHEMBL5291693 | 0.95 | KCNH2 (0.56) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 | |
| SCHEMBL5302157 | 0.95 | KCNH2 (0.56) | KMT2ASMN1; SMN2MEN1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | APPLIED NANOSYSTEMS B.V. (NL) | 2005-12-08 | — | — | US | disclosed |
| EP-1490028-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | Applied NanoSystems B.V. (NL) | 2004-12-29 | — | — | EP | disclosed |
| US-20040259823-A1 | Cationic amphiphiles as transfection vehicles | APPLIED NANOSYSTEMS B.V. (NL) | 2004-12-23 | — | — | US | disclosed |
| EP-1383745-A1 | CATIONIC AMPHIPHILES AS TRANSFECTION VEHICLES | Applied NanoSystems B.V. (NL) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003084508-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | APPLIED NANOSYSTEMS B.V. (NL) | 2003-10-16 | — | — | WO | disclosed |
| EP-1350507-A1 | Delivery of a substance to a pre-determinated site | Applied NanoSystems B.V. (NL) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002090329-A1 | CATIONIC AMPHIPHILES AS TRANSFECTION VEHICLES | APPLIED NANOSYSTEMS B.V. (NL) | 2002-11-14 | — | — | WO | disclosed |
| EP-1254896-A1 | Cationic amphiphiles, preparation and method for transfection | Applied NanoSystems B.V. (NL) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | TACR1, TACR2, NPSR1 | CHRM2 975/4885CHRM1 954/4885ACHE 1873/4885 |
| US-20040259823-A1 | Cationic amphiphiles as transfection vehicles | ANXA4, RNASEH1, NSUN3 | CHRM2 2769/4885CHRM1 2454/4885ACHE 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.